Physician profile

Ryan Tedford

Advanced Heart Failure and Transplant Cardiology · Charleston, SC

NPI 1104972751

$528,085.91

in general payments reported to CMS, 2019-2025

20 companies · $136K in 2025

The $136K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$282,249.08
Travel and Lodging$52,504.69
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$13,578.84
Food and Beverage$7,870.49
Honoraria$4,000.00
Education$61.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $247,370.11 2019-2025 Winrevair
Edwards Lifesciences Corporation $138,660.65 2021-2025
Abbott Laboratories $54,989.73 2019-2025 Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Freestyle Libre Pro
Abiomed $19,301.38 2019-2025 Impella
Endotronix, INC. $14,596.86 2024-2025 Cordella Pulomonary Artery Pressure Sensor, Cordella Pulmonary Artery Pressure Sensor
Medtronic, INC. $10,498.29 2022-2025 Linq II, Azure Xt Dr Mri Surescan
United Therapeutics Corporation $8,247.08 2019-2024 Tyvaso, Remodulin
Medtronic Vascular, INC. $7,921.19 2019
Boston Scientific Corporation $6,503.53 2024
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $6,000.00 2022-2024 Lifevest
Acceleron Pharma, INC. $5,340.00 2021
Cvrx, INC. $2,586.05 2022-2025 Barostim Neo System
Tempus Ai, INC $2,292.50 2024
Ancora Heart, INC. $2,213.10 2021
Actelion Pharmaceuticals US, INC. $1,118.30 2019-2024 Opsumit, Uptravi
Show all 20 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $231.17 2019
Boehringer Ingelheim Pharmaceuticals, INC. $92.48 2024 Jardiance
Sandoz INC. $76.45 2024 Treprostinil
Briohealth Solutions, INC. $32.27 2025 Briovad
Lightforce Orthodontics, INC. $14.77 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$520.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ryan Tedford

$528,085.91

in general payments reported 2019-2025

Years
2019-2025
Top company
Merck Sharp & Dohme LLC
Context
The $136K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).

https://glasscript.com/doctor/322937/ryan-tedford

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.